- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
home:diseases:ibs [03.13.2019] sallieq [Further researxh] |
home:diseases:ibs [03.15.2019] sallieq [Further research] |
||
|---|---|---|---|
| Line 53: | Line 53: | ||
| In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. (({{pubmed>long:25947920}})) | In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. (({{pubmed>long:25947920}})) | ||
| + | |||
| + | Mast cell activation syndromes (({{pubmed>long: 28780942}})) | ||
| + | |||
| + | Gastrointestinal (GI) symptoms are commonly reported in patients with mast cell disease. (({{pubmed>long: 30007461}})) | ||
| + | |||
| + | Mast cells are located in close proximity to the vasculature, and vasoactive mediators released upon their activation can promote endothelial activation leading to blood brain barrier (BBB) dysfunction. (({{pubmed>long: 30837844}})) | ||
| + | |||
| + | Mast cell activation plays an important role in stress-mediated disease pathogenesis. (({{pubmed>long:30837843}})) | ||
| + | |||
home/diseases/ibs.txt · Last modified: 03.15.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.